Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Preeclampsia
- Sponsor
- IRCCS San Raffaele
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- To construct reference ranges of placental angiogenesis markers specific to women with primary APS in pregnancy
- Status
- Recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS.
To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM).
For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.
Investigators
Rovere Querini Patrizia
Associate Professor of Internal Medicine, Vita-Salute San Raffaele University Head physician, U.O. General Medicine and Continuity of Care, IRCCS San Raffaele Hospital
IRCCS San Raffaele
Eligibility Criteria
Inclusion Criteria
- •Pregnant patients between the ages of 18 and 45 years.
- •Diagnosis of primary APS, according to international classification criteria.
- •Pregnant patients between the ages of 18 and 45 years.
- •Patients with at least one previous full-term pregnancy.
- •No diagnosis of APS, according to international classification criteria.
Exclusion Criteria
- •PMA pregnancies.
- •Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology
- •Previous thrombotic event
- •Chronic renal failure not related to AD
- •Previous history of oncology
- •Pregnancy by PMA.
- •Previous history of polyabortion and/or late pregnancy complications.
- •Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology
- •Previous thrombotic event
- •Previous history of oncology
Outcomes
Primary Outcomes
To construct reference ranges of placental angiogenesis markers specific to women with primary APS in pregnancy
Time Frame: six month after the end of the study
To construct reference ranges of placental angiogenesis markers specific to women with primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM).